The need to restate financial statements typically undermines investor confidence and can lead to a negative perception of the company's financial health and governance. This announcement directly impacts HCW Biologics and is likely to cause a short-term decline in its stock price due to the uncertainty and potential negative adjustments to its previously reported financial results.